Computer Science Faculty, University of Murcia, Murcia, Spain.
Computer Science Faculty, University of Murcia, Murcia, Spain.
Artif Intell Med. 2020 Jan;102:101751. doi: 10.1016/j.artmed.2019.101751. Epub 2019 Nov 13.
The current situation of critical progression in resistance to more effective antibiotics has forced the reuse of old highly toxic antibiotics and, for several reasons, the extension of the indications of combined antibiotic therapy as alternative options to broad spectrum empirical mono-therapy. A key aspect for selecting an appropriate and adequate antimicrobial therapy is that prescription must be based on local epidemiology and knowledge since many aspects, such as prevalence of microorganisms and effectiveness of antimicrobials, change from hospitals, or even areas and services within a single hospital. Therefore, the selection of combinations of antibiotics requires the application of a methodology that provides objectivity, completeness and reproducibility to the analysis of the detailed microbiological, epidemiological, pharmacological information on which to base a rational and reasoned choice.
We proposed a methodology for decision making that uses a multiple criteria decision analysis (MCDA) to support the clinician in the selection of an efficient combined empiric therapy. The MCDA includes a multi-objective constrained optimization model whose criteria are the maximum efficacy of therapy, maximum activity, the minimum activity overlapping, the minimum use of restricted antibiotics, the minimum toxicity of antibiotics and the activity against the most prevalent and virulent bacteria. The decision process can be defined in 4 steps: (1) selection of clinical situation of interest, (2) definition of local optimization criteria, (3) definition of constraints for reducing combinations, (4) manual sorting of solutions according to patient's clinical conditions, and (5) selection of a combination.
In order to show the application of the methodology to a clinical case, we carried out experiments with antibiotic susceptibility tests in blood samples taken during a five years period at a university hospital. The validation of the results consists of a manual review of the combinations and experiments carried out by an expert physician that has explained the most relevant solutions proposed according to current clinical knowledge and their use.
We show that with the decision process proposed, the physician is able to select the best combined therapy according to different criteria such as maximum efficacy, activity and minimum toxicity. A method for the recommendation of combined antibiotic therapy developed on the basis of a multi-objective optimization model may assist the physicians in the search for alternatives to the use of broad-spectrum antibiotics or restricted antibiotics for empirical therapy. The decision proposed can be easily reproduced for any local epidemiology and any different clinical settings.
目前,由于更有效的抗生素出现耐药性而导致治疗无效的情况日益严重,因此需要重新使用旧的高毒性抗生素,并且出于多种原因,将联合抗生素治疗的适应证扩展为广谱经验性单药治疗的替代方案。选择适当和充分的抗菌治疗的一个关键方面是,处方必须基于当地的流行病学和知识,因为许多方面,如微生物的流行和抗生素的有效性,在医院之间,甚至在一个医院内的不同区域和科室之间都有所不同。因此,抗生素联合的选择需要应用一种方法,该方法为基于合理和有根据的选择来分析详细的微生物学、流行病学和药理学信息提供客观性、完整性和可重复性。
我们提出了一种决策方法,使用多准则决策分析(MCDA)来支持临床医生选择有效的经验性联合治疗。MCDA 包括一个多目标约束优化模型,其标准是治疗的最大疗效、最大活性、最小活性重叠、限制使用抗生素的最小量、抗生素的最小毒性和对抗最常见和最具毒性的细菌的活性。决策过程可以分为 4 个步骤:(1)选择感兴趣的临床情况,(2)定义局部优化标准,(3)定义减少组合的约束,(4)根据患者的临床情况手动对解决方案进行排序,以及(5)选择一种组合。
为了展示该方法在临床病例中的应用,我们在一所大学医院的五年期间进行了血液样本抗生素药敏试验实验。结果的验证包括对组合的手动审查和一位专家医生进行的实验,该医生根据当前的临床知识解释了根据最相关的解决方案及其用途。
我们表明,通过所提出的决策过程,医生可以根据最大疗效、活性和最小毒性等不同标准选择最佳的联合治疗方案。基于多目标优化模型开发的联合抗生素治疗推荐方法可以帮助医生在经验性治疗中寻找替代广谱抗生素或限制抗生素的方法。提出的决策可以轻松地针对任何当地的流行病学和不同的临床情况进行复制。